Saturday, November 18, 2017
Health

Moffitt research offspring moves beyond cancer

RECOMMENDED READING


TAMPA — M2Gen is in a pitched race to stay ahead of its biotech competition.

The for-profit research arm of H. Lee Moffitt Cancer Center, M2Gen marshals computer calculating power to match genetic markers in patients to find and custom-tailor the right treatment.

It's heady stuff in a field that changes so rapidly it's easy to get left behind.

For 5-year-old M2Gen, that means broadening its scope for the first time beyond cancer to other diseases, including heart, circulation, diabetes and obesity. It also means partnering with research labs, hospitals and drugmakers that want access to its patented learning technology, and hiring investment bankers to land investors willing to bankroll acceleration of its work.

"The work we've done on cancer can be applied to finding the best treatments for other diseases," said Dr. William Dalton, Moffitt's chief executive.

The moves come at a critical time for M2Gen, which over its five years has spent more than $137 million in public and private investments and lost about $900,000 on revenue of about $10 million in 2011. Moffitt has contributed about $5 million and a $1.5 million line of credit to M2Gen.

The job is important enough that Dalton is leaving his $1.1-million-a-year job leading Moffitt to become M2Gen CEO in July.

"I asked to do it because I am passionate about making this happen," said Dalton 62, who turned over control of Moffitt to groomed successors Drs. Alan List and Thomas Sellers, as chief executive and center medical director, respectively.

The numbers underscore the downside of Tampa Bay and Florida governments' economic development strategy to become a hub for biotech medical research: Findings are elusive, returns on investment take a long time and sure things are rare.

"It's incredibly expensive and the technology changes so fast that we are seeing improvements in DNA sequencing that were inconceivable just two years ago," said Dr. Boris Pasche, director of hematology and oncology at the University of Alabama at Birmingham.

The first five-year partnership with Merck & Co., which poured $60 million in cash and $30 million in in-kind services into cancer research, ended Dec. 31 with the drug giant signing on for another year at a lower rate while giving up exclusive rights.

That freed M2Gen to sign up two drugmakers (that the company would not identify) and strike a vascular medicine research partnership with Sanford-Burnham Institute in Orlando and the Florida Hospital, the state's largest hospital network.

M2Gen is talking about taking on biorepository storage work for a new state-funded USF College of Medicine research partnership proposed with the American Cardiology Society.

Moffitt this month launched what it calls the Personalized Medical Institute to oversee collaborations with M2Gen.

Similar to Moffitt's pioneering Total Cancer Care therapy, which has been a national frontrunner for a decade, personalized care is the latest buzzword for moving modern medicine from a "find it and try to fix it" mentality to a predictive, preventative one. One way to get there is by linking genetic markers to treatments that worked best based on similar cases tracked by a huge and ever-growing database. Therapy decisions that once took days or weeks theoretically could take minutes.

M2Gen helps by applying its research learning machinery. So far, M2Gen has used only 20 percent of its 2.5 million tissue-sample freezer and, with Oracle, has developed patented software that matches and groups patient markers with successful treatments. The database, which has grown from only Moffitt patients to those treated at 18 facilities in 10 states, now stores and tracks tumor samples of 85,000 patients. Patients are tracked for life, learn whenever a new treatment is found that might benefit them and have access to their digital record.

To get to more meaningful results faster, however, M2Gen's patient database needs hundreds of thousands if not millions of samples. Meantime, a down economy and a wave of mergers muted much of drugmakers' interest in discovery. Plus the medical research world has changed since M2Gen was conceived eight years ago.

"Moffitt was first to build a cancer database, but everybody is doing that now," Pasche said. "It's going to be hard to generate much cash selling the information. Their only real advantage is already having one of the largest databases."

That's why Dalton wants to step up M2Gen's growth before others catch up.

"We have to get into more data gathering, we need to develop a modeling business and we need more partners," he said, predicting doubled or tripled revenues and profitability in a year or two.

With Merck, M2Gen looked for ways to shorten the time and expense of clinical testing for new drugs. In one venture with the National Cancer Institute, for instance, M2Gen found and tested 37 colon cancer patients who genetically met certain illness requirements in 10 months, a fraction of the normal time.

The Affordable Healthcare Act promises to prod hospitals to computerize their patient's medical treatment records far beyond the 1.5 percent that do now. Only about 3 percent of patients ever get in clinical trials, while Dalton cites studies suggesting two-thirds would benefit from them. That's why he sees a huge opportunity to save on health care costs by linking patient history to marker-matching databases that prescribe the right therapy the first time. Ultimately, he sees patients carrying their entire electronic medical record on a card.

But that's years away. Meanwhile, the management shuffle has produced some grumbling among the rank and file at Moffitt, a nonprofit that generated $566 million in annual revenue in 2011. The 204-bed clinic and research institute, which employs 4,400, is coping with a rising flow of patients and declining revenue per patient because of reduced Medicare and Medicaid payments and tighter government research grants.

Dalton concedes Moffitt faces some belt tightening, but thinks he can avoid layoffs. Help, too, is coming from the Legislature, which just earmarked $5 million in annual revenue from state cigarette taxes for 20 years that will help bankroll construction of the Moffitt campus on McKinley Avenue, north of Busch Gardens, in Tampa.

"But we cannot afford a bunker mentality," he said. "We need to generate new sources of revenue for Moffitt like M2Gen. And to maintain our top reputation we have to be smart about staying on the creative edge of medical innovation."

Moffitt, which owns all of M2Gen, hired investment bankers to find investors interested in providing expansion cash in return for minority ownership. Moffitt would keep controlling interest and share in the M2Gen revenue while keeping ownership of the freezer repository. How much is raised will guide the speed of Dalton's acceleration plans.

The state, city of Tampa and Hillsborough County spent about $37 million in tax money to launch M2Gen in 2006 in return for 160 new jobs. M2Gen has met the local government requirements, which were based on job creation to boost the economic development promise of the bay area's life sciences research cluster. Most of the money went into land and equipping a new building M2Gen rents from Moffitt.

"We have an educational mission to help build the Tampa Bay life sciences cluster," Dalton said. "That requires being at the forefront to keep attracting top talent. They will create more jobs and spinoff businesses. Having talent there is why Boston and the Research Triangle (in North Carolina) attract leading-edge research while Tampa is still seen as somewhat risky."

Mark Albright can be reached at [email protected] or (727) 893-8252.

Comments
New shingles vaccine touted as a breakthrough for older adults

New shingles vaccine touted as a breakthrough for older adults

Medical researchers and government health policymakers, a cautious lot, normally take pains to keep expectations modest when they’re discussing some new finding or treatment.They warn about studies’ limitations. They point out what isn’t known. They ...
Published: 11/17/17
In Tampa Bay and elsewhere, early numbers show record sign-ups for Obamacare

In Tampa Bay and elsewhere, early numbers show record sign-ups for Obamacare

Despite the budget cuts, the attempts to repeal and replace, and reports of sharp rises in premiums, Floridians and other Americans are signing up for health insurance under the Affordable Care Act at record rates this year.Enrollment has surged 47 p...
Published: 11/16/17
Updated: 11/17/17
Study: Mental quickness exercises can lower risk of dementia

Study: Mental quickness exercises can lower risk of dementia

Where did I leave my keys?As we age, it can take longer to answer a question like that.Humans begin to lose cognitive ability at age 25. Dementia, or the decline of memory most commonly seen in aging adults, takes hold early on and is gradual, but ac...
Published: 11/16/17
Blood pressure of 130 is the new ‘high,’ according to update of guidelines

Blood pressure of 130 is the new ‘high,’ according to update of guidelines

The nation’s heart experts tightened the guidelines for high blood pressure Monday, a change that will sharply increase the number of U.S. adults considered hypertensive in the hope that they, and their doctors, will address the deadly condition earl...
Published: 11/13/17
Are Honey Nut Cheerios healthy? A look inside the box

Are Honey Nut Cheerios healthy? A look inside the box

I had a bowl of Honey Nut Cheerios recently. It had been awhile. Regular Cheerios are more my thing. But sometimes I finish my box faster than my kids do and find myself straying to their side of the cupboard.Honey Nut is America’s best-selling break...
Published: 11/11/17
Owner of Bayfront Health St. Petersburg faces federal inquiry over funds for low-income patients

Owner of Bayfront Health St. Petersburg faces federal inquiry over funds for low-income patients

The corporate owner of Bayfront Health St. Petersburg could be facing a serious federal investigation related to its commitment to take care of St. Petersburg’s poorest residents.In its most recent filing with the U.S. Securities and Exchange Commiss...
Published: 11/09/17
Updated: 11/14/17
Learn to practice gratitude year-round, not just on Thanksgiving

Learn to practice gratitude year-round, not just on Thanksgiving

Is it part of your Thanksgiving tradition to go around the dinner table and have everyone share one thing they are thankful for? The exercise reminds us that the day is about more than just turkey and pie. And, for those who take it seriously, it for...
Published: 11/07/17
Updated: 11/10/17
When the goal is getting to the ER fast and cheap, some choose Uber over 911

When the goal is getting to the ER fast and cheap, some choose Uber over 911

Matt Lavin had just arrived in Charlottesville, Va., for a business trip when he started feeling sick. By the time he got to his hotel around 11 p.m., he felt excruciating pain. "I didn’t know what was happening, but I knew something wasnR...
Published: 11/06/17

Stunning study: Heart stents fail to ease chest pain

A procedure used to relieve chest pain in hundreds of thousands of heart patients each year is useless for many of them, researchers reported Wednesday.Their study focused on the insertion of stents, tiny wire cages, to open blocked arteries. The dev...
Updated one month ago
Vigil calls attention to overdose victims, and brings hope

Vigil calls attention to overdose victims, and brings hope

NEW PORT RICHEY — The room was filling up fast. For Monica Rousseau, the sight of so many people searching for a seat at the annual Narcotics Overdose Prevention and Education candlelight vigil was both heartbreaking and uplifting. "I can’t even gues...
Updated one month ago